METHOD FOR TREATING HEMATOLOGICAL CANCERS
Methods and compositions for treating hematological cancer are disclosed, including refractory or resistant hematological cancer.
1 . A method of treating hematological cancer, comprising administering to a patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof,
wherein R 1 represents hydrogen, a halogen or a sulfono group SO 3 M, in which M is a metal ion, and R 2 represents hydrogen, or R 1 is Cl and R 2 is I.
2 . The method of claim 1 , wherein said compound is tris(8-quinolinolato)gallium(III).
3 . The method of claim 2 , wherein said hematological cancer is acute myeloblastic leukemia, acute megakaryoblastic leukemia, chronic myelogenous leukemia, acute monocytic leukemia, myelodysplastic syndromes (MDS), or myeloproliferative diseases.
4 . The method of claim 2 , wherein said hematological cancer is of lymphoid origin.
5 . The method of claim 2 , wherein said hematological cancer is B-cell leukemia or T-cell leukemia.
6 . The method of claim 2 , wherein said hematological cancer is lymphoblastic or lymphocytic leukemia.
7 . The method of claim 2 , wherein said hematological cancer is multiple myeloma.
8 . The method of claim 2 , wherein said hematological cancer is Hodgkin's lymphoma or non-Hodgkin's lymphoma.
9 . The method of claim 2 , wherein said hematological cancer is a refractory hematological cancer.
10 . The method of claim 9 , wherein said hematological cancer is refractory to a treatment comprising one or more drugs selected from the group consisting of vinca alkaloids, anthracyclines, anthracenediones, epipodophyllotoxins, camptothecins, lenalidomide, thalidomide, cytarabine and fludarabine.
11 . The method of claim 9 , wherein said hematological cancer is non-Hodgkin's lymphoma, Hodgkin's lymphoma or acute lymphoblastic leukemia, which was previously treated with vincristine, vinblastine or vinorelbine.
12 . The method of claim 9 , wherein said hematological cancer is leukemia, Hodgkin's lymphoma, or multiple myeloma, which was previously treated with doxorubicin, daunorubicin, or epirubicin.
13 . The method of claim 9 , wherein said hematological cancer is non-Hodgkins lymphoma previously treated with an anthracenedione (e.g., mitoxantrone or pixantrone).
14 . The method of claim 9 , wherein said hematological cancer is previously treated with a camptothecin drug (e.g., topotecan).
15 . The method of claim 9 , wherein said hematological cancer is chronic myelogenous leukemia (CML)) previously treated with a PDGF-Rβ inhibitor (e.g., imatinib).
16 . The method of claim 9 , wherein said hematological cancer is multiple myeloma previously treated with lenalidomide or thalidomide.
17 . The method of claim 9 , wherein said hematological cancer is acute myeloid leukemia, acute lymphocytic leukemia (ALL) or lymphoma previously treated with cytarabine.
18 . The method of claim 9 , wherein said hematological cancer is chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma, or acute myeloid leukemia (AML) previously treated with fludarabine.
19 . The method of claim 9 , wherein said hematological cancer is lymphoma previously treated with one or more drugs chosen from cyclophosphamide, adriamycin, vincristine, and prednisone.
20 . The method of claim 9 , wherein said hematological cancer is MDS previously treated with lenalidomide.